文献速递肾小球疾病

补体C3a与C3a受体激活介导原发性膜性肾病机制中的足细胞损伤

Complement C3a and C3a Receptor Activation Mediates Podocyte Injuries in the Mechanism of Primary Membranous Nephropathy.
PubMed 文献 · J Am Soc Nephrol · 2022-07-01

本研究探讨C3a/C3aR在原发性膜性肾病(MN)足细胞损伤中的作用。MN患者肾小球C3aR过表达与蛋白尿、血肌酐及治疗无反应正相关;MN血浆可致人足细胞损伤,C3aR拮抗剂可阻断;Heymann肾炎大鼠中C3aR阻断减轻蛋白尿、电子致密物沉积、足突宽度及基底膜增厚,并降低特异性IgG沉积及补体活化。

要点

  • MN患者肾小球C3aR过表达与蛋白尿、血肌酐及治疗无反应正相关。
  • C3aR拮抗剂可阻断MN血浆诱导的人足细胞损伤。
  • Heymann肾炎大鼠中C3aR阻断减轻蛋白尿及足细胞损伤。

核心结论

  • C3a过敏毒素是MN中补体介导足细胞损伤的关键效应分子。
  • C3aR拮抗剂可能是该病的潜在可行治疗。

研究设计与样本

  • 检测MN患者肾脏C3aR表达及循环C3a水平。
  • 人足细胞暴露于MN血浆±C3aR阻断(SB290157、JR14a)后评估损伤。
  • Heymann肾炎大鼠在第0天或出现蛋白尿后给予C3aR拮抗剂,评估临床病理参数、特异性IgG与补体活化及足细胞损伤。

主要发现

  • 肾小球中C3aR染色与podocin良好融合。
  • C3aR过表达与蛋白尿、血清肌酐及对治疗无反应呈正相关。
  • MN血浆暴露的人足细胞PLA2R、C3aR及Wnt3/β-catenin表达增加,synaptopodin表达和迁移功能降低,Bcl-2下调,细胞活力下降;C3aR拮抗剂可阻断这些效应。
  • Heymann肾炎大鼠中C3aR阻断减轻蛋白尿、电子致密物沉积、足突宽度及肾小球基底膜增厚,并缓解血浆C3a升高和C3aR过表达。
  • 特异性IgG(而非总IgG)水平降低,肾小球大鼠IgG沉积减少,随后C1q、factor B及C5b-9减少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The complement system is highly activated in primary membranous nephropathy (MN). Identifying the complement components that damage podocytes has important therapeutic implications. This study investigated the role of C3a and the C3a receptor (C3aR) in the pathogenesis of MN. METHODS: C3aR expression in kidneys and circulating levels of C3a of MN patients were examined. Human podocyte damage was assessed after exposure to MN plasma +/- C3aR blockade (SB290157, JR14a). C3aR antagonists were administered to rats with Heymann nephritis on day 0 or after proteinuria. Clinical and pathologic parameters, specific IgG and complement activation, and podocyte injuries were then assessed. RESULTS: In the glomeruli, C3aR staining merged well with podocin. Overexpression of C3aR correlated positively with proteinuria, serum creatinine, and no response to treatments. Human podocytes exposed to MN plasma showed increased expression of PLA2R, C3aR, and Wnt3/β-catenin, reduced expression of synaptopodin and migration function, downregulated Bcl-2, and decreased cell viability. C3aR antagonists could block these effects. In Heymann nephritis rats, C3aR blockade attenuated proteinuria, electron-dense deposition, foot process width, and glomerular basement membrane thickening in glomeruli. The increased plasma C3a levels and overexpression of C3aR were also alleviated. Specific, but not total, IgG levels decreased, with less deposition of rat IgG in glomeruli and subsequent reduction of C1q, factor B, and C5b-9. CONCLUSION: C3a anaphylatoxin is a crucial effector of complement-mediated podocyte damage in MN. The C3aR antagonist may be a potentially viable treatment for this disease.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Gao S, Cui Z, Zhao MH, et al. Complement C3a and C3a Receptor Activation Mediates Podocyte Injuries in the Mechanism of Primary Membranous Nephropathy. J Am Soc Nephrol. 2022. PMID: 35777783. doi:10.1681/ASN.2021101384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。